Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 12

Results: 9

Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson's Disease.

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1249, doi. 10.1007/s40263-022-00973-7

By:

Patel, Jaimin;
Panicker, Nikhil;
Dawson, Valina L.;
Dawson, Ted M.

Publication type:

Article

Acknowledgement to Referees.

Published in:: CNS Drugs, 2022, v. 36, n. 12, p. 1243, doi. 10.1007/s40263-022-00972-8
Publication type:: Article

Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis.

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1313, doi. 10.1007/s40263-022-00971-9

By:

Ip, Bonaventure Y.;
Ko, Ho;
Wong, Grace LH;
Yip, Terry CF;
Lau, Louis HS;
Lau, Alexander YL;
Leng, Xinyi;
Leung, Howan;
Chan, Howard HW;
Chan, Helen YF;
Mok, Vincent CT;
Soo, Yannie OY;
Leung, Thomas W.

Publication type:

Article

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients.

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1301, doi. 10.1007/s40263-022-00970-w

By:

Yang, Hui;
Zhang, YuJun;
Liu, ChuiLiang;
Ou, YangWen;
Zhu, YuHang;
Xue, Yun;
Zhao, GaoFeng;
Lin, YuShuang;
Chen, Chun;
Xu, GuoHai;
Yuan, KaiMing;
Wang, Qiang;
Zhang, Min;
Li, LiE;
Liu, Jin;
Zhang, WenSheng

Publication type:

Article

Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects.

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1325, doi. 10.1007/s40263-022-00969-3

By:

Witt, Juri-Alexander;
Widman, Guido;
Hansen, Niels;
von Wrede, Randi;
Elger, Christian E.;
Helmstaedter, Christoph

Publication type:

Article

Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1333, doi. 10.1007/s40263-022-00967-5

By:

Nasser, Azmi;
Hull, Joseph T.;
Liranso, Tesfaye;
Fry, Nicholas;
Cutler, Andrew J.;
Rubin, Jonathan;
Childress, Ann

Publication type:

Article

Comment on: "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder".

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1331, doi. 10.1007/s40263-022-00966-6

By:

Singh, Alok;
Balasundaram, Mahesh Kumar

Publication type:

Article

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis.

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1285, doi. 10.1007/s40263-022-00965-7

By:

Freeman, Léorah;
Longbrake, Erin E.;
Coyle, Patricia K.;
Hendin, Barry;
Vollmer, Timothy

Publication type:

Article

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.

Published in:

CNS Drugs, 2022, v. 36, n. 12, p. 1269, doi. 10.1007/s40263-022-00963-9

By:

Antonini, Angelo;
Pahwa, Rajesh;
Odin, Per;
Isaacson, Stuart H.;
Merola, Aristide;
Wang, Lin;
Kandukuri, Prasanna L.;
Alobaidi, Ali;
Yan, Connie H.;
Bao, Yanjun;
Zadikoff, Cindy;
Parra, Juan Carlos;
Bergmann, Lars;
Chaudhuri, K. Ray

Publication type:

Article